Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity-matched cohort study.

IF 8.4 2区 医学 Q1 DERMATOLOGY
Sophie L Preuß, Katja Bieber, Artem Vorobyev, Andreas Recke, Eva Lotta Moderegger, Henner Zirpel, Evelyn Gaffal, Diamant Thaçi, Khalaf Kridin, Ralf J Ludwig
{"title":"Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity-matched cohort study.","authors":"Sophie L Preuß, Katja Bieber, Artem Vorobyev, Andreas Recke, Eva Lotta Moderegger, Henner Zirpel, Evelyn Gaffal, Diamant Thaçi, Khalaf Kridin, Ralf J Ludwig","doi":"10.1111/jdv.20670","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Type 2 chronic inflammatory diseases (T2IDs) are highly prevalent among women of reproductive age. Dupilumab, a monoclonal antibody, is increasingly used to treat T2IDs. While dupilumab is not approved during pregnancy, smaller studies suggest no increased risk of pregnancy complications (adverse pregnancy outcomes (APOs)). Additional data are required to better assess the drug's safety during pregnancy.</p><p><strong>Objectives: </strong>To retrospectively assess the risk of APOs in dupilumab-treated pregnant women in a large real-world database.</p><p><strong>Methods: </strong>Pregnant women with T2ID and dupilumab treatment during pregnancy were retrieved from the US Collaborative Network of TriNetX. Pregnant women with T2ID and without dupilumab treatment served as controls. Propensity score matching (PSM) for demographics, diagnoses, medications and putative APO risk factors was employed. Outcomes analysed included various maternal pregnancy complications, including premature obstetric labour, pregnancy-induced hypertension, gestational diabetes, puerperal infections and spontaneous abortion. Survival analyses were assessed using the Kaplan-Meier method, outcome differences the log-rank test and hazard ratios (HR) the Cox regression model.</p><p><strong>Results: </strong>During pregnancy, 293 women were exposed to dupilumab. Following PSM, no increased risks for APOs were noted. Of note, reduced risks for premature obstetric labour (HR: 0.11, confidence interval (CI): 0.03-0.45, p = 0.0002) and 'any APO' (HR: 0.53, CI: 0.33-0.84, p = 0.0067) in the dupilumab-treated group were found. Furthermore, no difference in risks for any APO was noted between dupilumab-treated and untreated women up to 6 months before pregnancy or during the postpartum period.</p><p><strong>Conclusions: </strong>This large-scale propensity-matched retrospective cohort study suggests a favourable safety profile of dupilumab during pregnancy. Given the difficulties of prospective studies during pregnancy, it provides valuable insights, though further studies are needed to confirm these findings and explore causal relationships.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the European Academy of Dermatology and Venereology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/jdv.20670","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Type 2 chronic inflammatory diseases (T2IDs) are highly prevalent among women of reproductive age. Dupilumab, a monoclonal antibody, is increasingly used to treat T2IDs. While dupilumab is not approved during pregnancy, smaller studies suggest no increased risk of pregnancy complications (adverse pregnancy outcomes (APOs)). Additional data are required to better assess the drug's safety during pregnancy.

Objectives: To retrospectively assess the risk of APOs in dupilumab-treated pregnant women in a large real-world database.

Methods: Pregnant women with T2ID and dupilumab treatment during pregnancy were retrieved from the US Collaborative Network of TriNetX. Pregnant women with T2ID and without dupilumab treatment served as controls. Propensity score matching (PSM) for demographics, diagnoses, medications and putative APO risk factors was employed. Outcomes analysed included various maternal pregnancy complications, including premature obstetric labour, pregnancy-induced hypertension, gestational diabetes, puerperal infections and spontaneous abortion. Survival analyses were assessed using the Kaplan-Meier method, outcome differences the log-rank test and hazard ratios (HR) the Cox regression model.

Results: During pregnancy, 293 women were exposed to dupilumab. Following PSM, no increased risks for APOs were noted. Of note, reduced risks for premature obstetric labour (HR: 0.11, confidence interval (CI): 0.03-0.45, p = 0.0002) and 'any APO' (HR: 0.53, CI: 0.33-0.84, p = 0.0067) in the dupilumab-treated group were found. Furthermore, no difference in risks for any APO was noted between dupilumab-treated and untreated women up to 6 months before pregnancy or during the postpartum period.

Conclusions: This large-scale propensity-matched retrospective cohort study suggests a favourable safety profile of dupilumab during pregnancy. Given the difficulties of prospective studies during pregnancy, it provides valuable insights, though further studies are needed to confirm these findings and explore causal relationships.

Dupilumab显示孕妇不良妊娠结局的风险没有升高:一项倾向匹配的队列研究。
背景:2型慢性炎症性疾病(T2IDs)在育龄妇女中非常普遍。Dupilumab是一种单克隆抗体,越来越多地用于治疗t2id。虽然dupilumab在妊娠期未被批准,但较小的研究表明,dupilumab不会增加妊娠并发症(不良妊娠结局(APOs))的风险。需要更多的数据来更好地评估该药物在怀孕期间的安全性。目的:在一个大型真实世界数据库中回顾性评估dupilumab治疗的孕妇发生apo的风险。方法:从美国TriNetX合作网络检索妊娠期T2ID和dupilumab治疗的孕妇。未接受dupilumab治疗的T2ID孕妇作为对照组。采用倾向评分匹配(PSM)对人口统计学、诊断、药物和假定的APO危险因素进行分析。结果分析包括各种孕产妇妊娠并发症,包括早产、妊娠高血压、妊娠糖尿病、产褥期感染和自然流产。生存分析采用Kaplan-Meier法,结果差异采用log-rank检验,风险比(HR)采用Cox回归模型。结果:在怀孕期间,293名妇女暴露于dupilumab。在PSM后,apo的风险没有增加。值得注意的是,dupilumumab治疗组的早产风险降低(HR: 0.11,可信区间(CI): 0.03-0.45, p = 0.0002)和“任何APO”(HR: 0.53, CI: 0.33-0.84, p = 0.0067)。此外,在妊娠前6个月或产后,dupilumumab治疗和未治疗的妇女发生APO的风险没有差异。结论:这项大规模倾向匹配的回顾性队列研究表明,dupilumab在妊娠期间具有良好的安全性。考虑到怀孕期间前瞻性研究的困难,它提供了有价值的见解,尽管需要进一步的研究来证实这些发现并探索因果关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.70
自引率
8.70%
发文量
874
审稿时长
3-6 weeks
期刊介绍: The Journal of the European Academy of Dermatology and Venereology (JEADV) is a publication that focuses on dermatology and venereology. It covers various topics within these fields, including both clinical and basic science subjects. The journal publishes articles in different formats, such as editorials, review articles, practice articles, original papers, short reports, letters to the editor, features, and announcements from the European Academy of Dermatology and Venereology (EADV). The journal covers a wide range of keywords, including allergy, cancer, clinical medicine, cytokines, dermatology, drug reactions, hair disease, laser therapy, nail disease, oncology, skin cancer, skin disease, therapeutics, tumors, virus infections, and venereology. The JEADV is indexed and abstracted by various databases and resources, including Abstracts on Hygiene & Communicable Diseases, Academic Search, AgBiotech News & Information, Botanical Pesticides, CAB Abstracts®, Embase, Global Health, InfoTrac, Ingenta Select, MEDLINE/PubMed, Science Citation Index Expanded, and others.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信